Lipigon initially focuses on rare diseases that may qualify for orphan drug status as well as niche indications. This strategy enables faster market access and cost-effective development while offering the potential for market exclusivity and attractive pricing.

The company manages a portfolio comprising four projects with unique mechanisms of action, each holding the potential for broader indications. Currently, three of these projects are actively under development.

Lipigon's research efforts are mainly focused on lipid management. However, Project 4 represents a deviation as it is now aimed at the treatment and prevention of lung injuries related to Community Acquired Pneumonia (CAP).

The most advanced project, Lipisense® (P1), is in the clinical phase. This RNA-based drug candidate aims to reduce triglyceride levels in patients' blood.